(Q35625911)

English

Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder

scientific article published on October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

Theresa Winhusen

1

object named as

Theresa M Winhusen

1 reference

Europe PubMed Central

9 August 2017

author name string

Daniel F Lewis

2

1 reference

Europe PubMed Central

9 August 2017

Paula D Riggs

3

1 reference

Europe PubMed Central

9 August 2017

Robert D Davies

4

1 reference

Europe PubMed Central

9 August 2017

Lenard A Adler

5

1 reference

Europe PubMed Central

9 August 2017

Susan Sonne

6

1 reference

Europe PubMed Central

9 August 2017

Eugene C Somoza

7

1 reference

Europe PubMed Central

9 August 2017

publication date

1 October 2011

1 reference

Europe PubMed Central

9 August 2017

Journal of Child and Adolescent Psychopharmacology

1 reference

Europe PubMed Central

9 August 2017

21

1 reference

Europe PubMed Central

9 August 2017

5

1 reference

Europe PubMed Central

9 August 2017

455-463

1 reference

Europe PubMed Central

9 August 2017

Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

The worldwide prevalence of ADHD: is it an American condition?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

Assessing methylphenidate preference in ADHD patients using a choice procedure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

Dual diagnosis and successful participation of adolescents in substance abuse treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

The stimulants revisited.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

Stimulant medications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

12 July 2018

Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

25 September 2018

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

25 September 2018

A pilot study of methylphenidate preference assessment in children diagnosed with attention-deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

25 September 2018

Psychostimulant Treatment and Risk for Substance Abuse Among Young Adults with a History of Attention-Deficit/Hyperactivity Disorder: APopulation-Based, Birth Cohort Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243465

7 December 2018

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/22040190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/22040190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do Formulation Differences Alter Abuse Liability of Methylphenidate?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22040190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/CAP.2011.0014

1 reference

Europe PubMed Central

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35625911&oldid=2126793169"